

# Can L-Carnitine Replace Tumor Necrosis Factor-Alpha Blockers? A Systematic Review and Dose–Response Meta-Analysis

Farnaz Naeimzadeh<sup>1,2</sup>, Amirreza Naseri<sup>1</sup>, Sarvin Sanaei<sup>3</sup>, Seiedhadi Saghaleini<sup>4</sup>, Afshin Gharekhani<sup>2\*</sup>

<sup>1</sup>Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

<sup>2</sup>Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.

<sup>3</sup>Research Center for Integrative Medicine in Ageing, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.

<sup>4</sup>Clinical Research Development Unit, Sina Educational, Research and Treatment Center, Tabriz University of Medical Sciences, Tabriz, Iran.

## Article Info

### Article History:

Received: 14 Feb 2024

Accepted: 21 Apr 2024

ePublished: 15 Jul 2024

### Keywords:

-Carnitine  
-Levocarnitine  
-Inflammation  
-Tumor Necrosis Factor-alpha

## Abstract

**Background:** L-carnitine (LC), an amino acid-like molecule, has been shown to reduce tumor necrosis factor-alpha (TNF- $\alpha$ ), although some research has not confirmed its impact. This study aimed to identify the effects of LC supplementation on TNF- $\alpha$  levels through a systematic review and meta-analysis of randomized controlled trials (RCTs).

**Methods:** This study followed the PRISMA 2020 statement and searched the Web of Science, PubMed, Embase, and Scopus for related papers on LC supplementation's effects on TNF- $\alpha$  in adults. The meta-analysis was performed using the 17th version of the Stata Statistical Software, and the  $I^2$  statistic was used to assess the impact of heterogeneity. The Cochrane risk of bias tool was used to evaluate the risk of bias in the included studies.

**Results:** Seventeen RCTs were included based on the full-text review, and the data from 14 studies were included in the meta-analysis. Based on the results, oral LC did not have a significant impact on TNF- $\alpha$  levels (Cohen's  $d$ : -0.19 [95% CI: -0.71 to 0.33];  $I^2$ : 97.39%). However, parenteral LC had significantly reduced TNF- $\alpha$  levels (Cohen's  $d$ : -1.60 [95% CI: -3.06 to -0.15];  $I^2$ : 88.92%). Oral LC doses of 0.75 and 6 g/day were effective, while duration of LC administration was associated with significant findings in 2, 36, and 48 weeks. The dose and duration of LC administration ineffective independently of TNF- $\alpha$  levels ( $P = 0.35$  and  $P = 0.70$  for dose and duration of administration, respectively).

**Conclusion:** In this meta-analysis, oral LC supplementation failed to be superior to TNF- $\alpha$  blockers.

## Introduction

Historically, inflammation has been a complex biological process linked to infection and the immune system. However, recent evidence suggests a much more comprehensive range of diseases are associated with inflammation.<sup>1-3</sup> For instance, non-resolving inflammation plays a key role in the pathogenesis of atherosclerosis, cancer, chronic obstructive pulmonary disease, obesity, asthma, inflammatory bowel disease, rheumatoid arthritis, neurodegenerative disease, depression, and multiple sclerosis.<sup>4,5</sup> Therefore, anti-inflammatory medicines that are effective in a specific inflammatory disease may prove effective in other inflammatory diseases and result in a broad range of intervention options. The prevalence of inflammatory diseases in developed western countries is 5–7% and is gradually increasing.<sup>6</sup> One of the main molecular mediators of chronic inflammation is tumor necrosis factor-alpha (TNF- $\alpha$ ).<sup>7</sup> As a result, TNF- $\alpha$  inhibitors such as the circulating receptor fusion protein

and monoclonal antibodies have been developed. However, these blockers come with serious side effects and are quite costly.<sup>8</sup> Consequently, there is a need for agents that are cost-benefit, and safe.

L-carnitine (LC), or L- $\beta$ -hydroxy- $\gamma$ -N-trimethylaminobutyric acid, is an amino acid-like molecule that is mainly used as a dietary supplement for several health indications.<sup>9</sup> LC is mainly synthesized in the kidneys and liver.<sup>10</sup> The essential role of LC is to transfer fatty acids into the mitochondrial matrix and make them available for  $\beta$ -oxidation, producing energy via the Krebs cycle.<sup>11</sup>

There are reports of the reduction of circulating TNF- $\alpha$  levels and inhibition of its action by LC according to in vitro and in animal models.<sup>12,13</sup> Some clinical trials have shown reduced levels of TNF- $\alpha$  after LC administration, which suppresses organ inflammation.<sup>14,15</sup> Inversely, the results of several other studies showed that LC administration had no significant effect on the level of this inflammatory

\*Corresponding Author: Afshin Gharekhani, E-mail: anqarekhani@yahoo.com

©2024 The Author(s). This is an open access article and applies the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>). Non-commercial uses of the work are permitted, provided the original work is properly cited.

factor.<sup>16-18</sup>

Although there are several randomized clinical trials (RCTs) to assess the effect of oral and intravenous LC on TNF- $\alpha$ , their results are contradictory. Some RCTs have suggested that LC has a reducing effect on reduces TNF- $\alpha$ , while others did not report any effect. However, the latest meta-analysis of 48 RCTs suggested a decreasing effect of LC on TNF- $\alpha$ .<sup>19</sup> This meta-analysis did not include new RCTs. Furthermore, this study mistakenly included an article that did not have TNF- $\alpha$  in its evaluated outcomes,<sup>20</sup> which seems to affect the final result. Finally, due to equivocal results of the most recent meta-analysis and the increasing prevalence of inflammatory diseases, we decided to investigate how LC influences TNF- $\alpha$  and compare the optimal oral and intravenous (IV) LC to healthy and unhealthy adults.

## Methods

The preparation of this systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<sup>21</sup>

### Eligibility criteria

Inclusion and exclusion criteria for study selection have been listed in Table 1.

### Information sources and search strategy

Two researchers (F.N. and A.N.) comprehensively searched the Web of Science, Scopus, Embase, and PubMed on December 31, 2023. Additionally, specific relevant papers and websites were manually searched. The reference lists of the chosen papers were evaluated. To find additional information about the related studies, the reference lists of the chosen articles and relevant review articles were manually searched. The database search results were imported into the Endnote X20 citation manager program for further analysis. After endnote software eliminated duplicate studies, the remaining papers were manually reviewed for duplication. Searches were performed using the keywords tumor necrosis factor, carnitine, l-carnitine, levocarnitine, vitamin b and other similar keywords. The search strategy in each database is detailed in supplementary data.

### Selection process

The database search results were imported into the Endnote 20 citation manager program for further analysis.

After endnote software eliminated duplicate studies, the remaining papers were manually reviewed for duplication. After removing duplicates, articles were selected by screening the title and abstract of the imported studies (F.N. and A.N.), and unrelated articles were removed. Two independent reviewers (F.N. and A.N.) thoroughly assessed the full text of the remaining studies. Any disagreements were resolved by another reviewer (S.S.<sup>1</sup>), and the consensus was achieved in all cases.

### Data collection process and data items

The data extraction table includes the name of the first author of the study, publication year, study design, sample size, age, BMI, underlying condition, LC dose, route of administration, follow-up duration, main results (consisting of TNF- $\alpha$  levels before and after administration of LC and placebo), and conclusion of the study. Two researchers (F.N. and A.N.) extracted the data, and two additional reviewers (A.GH. and S.S.<sup>1</sup>) examined and verified the accuracy of the extracted data. Disagreements were resolved by another reviewer (S.S.<sup>2</sup>), and in all cases, consensus was achieved.

### Study risk of bias assessment and certainty of the evidence

We assessed the potential for bias in the estimates of the impact of assignment to the intervention (intention-to-treat) for all outcomes via the Cochrane risk of bias tool (RoB2).<sup>22</sup> Potential bias was identified in five domains: the randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result. Additionally, an assessment of the overall risk of bias was performed. The risk of bias for each domain and the overall risk of bias were categorized as “low,” “some concerns,” or “high.” Two reviewers (F.N., A.N.) conducted this stage independently. Reviewers’ discrepancies were handled through discussion and, if consensus could not be achieved, by a third reviewer (S.S.<sup>2</sup>). Finally, the certainty of the evidence was assessed using the Cochrane GRADE approach.<sup>23</sup>

### Synthesis methods of results

The meta-analysis was conducted using the 17<sup>th</sup> version of the Stata Statistical Software (College Station, TX: StataCorp LLC.). The  $I^2$  statistic was used to quantify the effect of heterogeneity. A random-effect model was applied due to the considerable heterogeneity between the studies.

**Table 1.** Inclusion and exclusion criteria for selection of studies.

Inclusion Criteria	Exclusion Criteria
<ul style="list-style-type: none"> <li>Population: Adult patients whose inflammation plays a role in the pathophysiology of their disease.</li> <li>Intervention: L-carnitine administration in any route, alone or together with other agents</li> <li>Comparison: Placebo or other agent</li> <li>Outcome: tumor necrosis factor-alpha</li> <li>Study design: randomized clinical trials</li> </ul>	<ul style="list-style-type: none"> <li>Articles published in non-English language</li> <li>Non-randomized clinical trials, conference presentations, case reports, case series, and letters to the editor</li> <li>Community-based articles</li> <li>Animal studies</li> </ul>

The mean and standard deviation (SD) before and after the intervention for the LC and control groups were utilized to calculate the effect size. The SD change was calculated using the following equation.<sup>24</sup>

$$SD\ change = \sqrt{SD\ before^2 + SD\ after^2 - 2 * r * SD\ before * SD\ after} \quad Eq.(1)$$

Also, subgroup analyses based on g/day of LC usage and duration of treatment were conducted. Furthermore, 95% confidence intervals (CIs) and a 0.05 level of significance were observed in all the statistics. Meta-regression was performed based on grams per day and the duration of LC administration in weeks. The possibility of publication bias was assessed using Egger's test and presented by funnel plot.

## Results

### Study selection

Figure 1 illustrates the flow of articles through the search process. The search yielded 3643 studies. After deduplication, 1739 studies remained, and the initial screening phases provided us with 39 to evaluate. Finally,

17 RCTs were included in this systematic review according to the inclusion and exclusion criteria.

### Study characteristics

From a total of 17 RCTs, four took place in Iran,<sup>14,18,25,26</sup> six in Italy,<sup>15,17,27-30</sup> two in China,<sup>16,31</sup> one in Taiwan,<sup>32</sup> one in Egypt,<sup>33</sup> one in Malaysia,<sup>34</sup> one in Poland,<sup>35</sup> and one in the United States.<sup>36</sup> Ten RCTs were double-blinded,<sup>14,15,17,25,26,29,30,34-36</sup> two were single-blinded,<sup>31,32</sup> two open-label RCTs,<sup>16,18</sup> and three studies had unknown blinding.<sup>28,33,37</sup> A total of 1185 individuals were included and the sample size ranged from 20<sup>17,28</sup> to 258.<sup>30</sup> The mean number of patients among the studies was 69.71 and the mean follow-up duration was 14.55 weeks with a maximum and minimum of one day to 48 weeks. In terms of supplementation, various substances were used in each study. Ten studies used LC as their only intervention.<sup>14,17,18,25,26,32,35,36</sup> Except for three studies in which parenteral LC was administered,<sup>16,28,31</sup> LC was administered orally in the rest. The population of the studies was immensely heterogeneous. Table S1 in supplementary data shows a brief overview of the characteristics of the included studies.




Figure 1. PRISMA flow diagram.

**Risk of bias in studies**

The quality of the included studies was assessed using version 2 of the Cochrane risk-of-bias tool for randomized trials (Figure 2). Accordingly, three studies were considered high-risk,<sup>15,25,37</sup> and the rest were evaluated as “some concern.”<sup>14,16-18,26,28-36</sup> One study (24%) had a high risk of bias in the randomization process. Six studies (24%) had an unclear risk of bias for random sequence generation. For allocation concealment, eight studies (32%) had an unclear risk of bias. Blinding of the participant was unclear in two studies (8%), blinding of outcome assessment was high risk in one study (4%), and unclear in two studies (8%). Regarding attrition bias, all the RCTs had low risks of bias. High and unclear reporting bias was detected in thirteen (52%) and seven (28%) studies, respectively.

**Results of the synthesis**


The results of the meta-analysis are presented in Figure

3. Based on the quantitative synthesis, LC did not seem to have a considerable effect on TNF-α levels (Cohen’s d: -0.32 [95% CI: -0.83 to 0.20]; I<sup>2</sup>: 97.39%).


Subgroup analyses based on the route of LC administration showed that the impacts of IV and oral LC are different from each other. So in the subsequent analysis, we included only RCTs with oral LC administration. Oral LC did not significantly reduce TNF-α levels (Cohen’s d: -0.19 [95% CI: -0.71 to 0.33]; I<sup>2</sup>: 97.39%). However, IV LC was associated with a significant reduction in its levels (Cohen’s d: -1.60 [95% CI: -3.06 to -0.15]; I<sup>2</sup>: 88.92%) (supplementary data).

In subgroup analyses based on the dose of oral LC, we found only 0.75 and 6 g/day dosage as effective (Figure 4). In addition, the results of subgroup analyses based on the duration of LC usage in weeks were associated with significant findings in 2, 36, and 48 weeks (Figure 5).

According to the meta-regression, which was



**Figure 2.** The risk of the bias assessment of the included studies according to the Cochrane guidelines.



**Figure 3.** The results of meta-analysis based on dose of oral L-carnitine administration in grams/day.

performed based on grams per day and the duration of LC administration, none of them were effective independent of TNF- $\alpha$  levels ( $P = 0.35, P = 0.70$  for dose and duration of administration, respectively). The highest significant decrease in the TNF- $\alpha$  levels is 6 g/day for two weeks (Figure 6).

Meanwhile, the subgroup analysis was carried out based on country, revealing that the differences between countries may influence the results ( $P = 0.00$ ). The subgroup analysis showed that in Egypt, Italy, and Iran, the reduction of TNF- $\alpha$  levels after LC supplementation is statistically significant ( $P = 0.002, P = 0.00, \text{ and } P = 0.001$ , respectively) (supplementary data).

**Publication bias**


Figure 7 presents the funnel plot for the meta-analysis. There was no significant publication bias based on our assessments using Egger’s test (p-value: 0.43) and Begg’s test (p-value: 0.78) for minor study effects in the meta-analysis.

**Certainty of evidence**

All studies were RCTs; however, considering the concerns regarding the risk of bias, significant level of heterogeneity, and imprecision of results due to small sample sizes, the level of evidence for the effects of LC on TNF- $\alpha$  was moderate.

**Discussion**

In this meta-analysis, we evaluated the impact of LC administration on TNF- $\alpha$  levels. Our findings revealed that oral LC supplementation did not significantly decrease TNF- $\alpha$  levels. However, IV administration reduced its levels significantly. Subgroup analyses based on oral LC dose revealed that only 0.75 and 6 g/day efficiently reduced TNF- $\alpha$  levels. Furthermore, subgroup analyses based on the duration of LC administration in weeks yielded significant outcomes in 2, 36, and 48 weeks. According to the meta-regression, which was based on grams per day and the duration of LC supplementation, we found that none of them were effective on TNF- $\alpha$  levels independently. In the meantime, the country-based subgroup analysis showed



Random-effects REML model

Figure 4. The results of meta-analysis based on dose of oral L-carnitine administration in grams/day.






Figure 5. The results of meta-analysis based on the duration of oral L-carnitine administration in weeks.



**Figure 6.** The results of meta-regression based on dose of oral L-carnitine in grams/day and the duration administration in weeks.



**Figure 7.** Funnel plot detailing publication bias in the studies reporting the impact of L-carnitine on plasma TNF- $\alpha$  concentrations.

that the variations among countries might impact TNF- $\alpha$  levels.

The US FDA has approved TNF- $\alpha$  blockers, such as adalimumab, etanercept, and infliximab, for the treatment of treating several inflammatory chronic diseases. However, they have a long list of serious severe side effects, such as pancytopenia, thrombocytopenia, leukopenia, neutropenia, and liver damage.<sup>38</sup> Thus, it would appear that safer alternatives are required. This meta-analysis assessed LC's impact on TNF- $\alpha$  as a potential safer alternative. From the pathophysiological point of view, nuclear factor kappa B (NF- $\kappa$ B) is a transcription factor that regulates the immune system's functions and inflammatory cascades. It induces pro-inflammatory genes, participates in inflammasome regulation, and plays a critical role in innate immune cell survival and differentiation. Deregulated NF- $\kappa$ B activation contributes to inflammatory diseases.<sup>39</sup> LC inhibits the activation of NF- $\kappa$ B and subsequently prevents the induction of inflammatory cytokines such as TNF- $\alpha$ .<sup>40</sup> In certain studies, LC supplementation significantly decreased TNF- $\alpha$  concentrations compared to

a placebo.<sup>15,29,32</sup> However, other researches failed to identify any significant reduction.<sup>16-18</sup> For example, Sawicka *et al.*<sup>35</sup> could not show any significant effects of LC supplementation at a dosage of 1,500 mg/day for 24 weeks on TNF- $\alpha$  concentration in healthy women older than 65. In another study in hemodialysis patients, IV administration of LC 1 g/day after each hemodialysis session for three months did not change the circulating TNF- $\alpha$  levels.<sup>16</sup> Carnitine is a general term for all kinds of compounds. The most common among them in the body and supplements is L-carnitine. Other analogs include acetyl L-carnitine, propionyl L-carnitine, and L-carnitine L-tartrate. Studies have shown that the bioavailability of carnitine analogs is different from each other. Acetyl L-carnitine is the most bioavailable analog.<sup>41</sup> Perhaps one of the reasons for the significant difference in the results of different studies was the administration of different LC analogues. Another reason can be due to the different disease conditions in the included studies. Also, the influence of the difference in demographic characteristics of patients in the studies cannot be ignored. For example, higher TNF- $\alpha$  concentrations correlated with increasing age<sup>42</sup> and increasing adiposity.<sup>43</sup>

The findings showed that LC did not influence have a significant impact on TNF- $\alpha$  levels significantly. In contrast to our findings, the latest meta-analysis by Rastgoo *et al.*<sup>19</sup> reported a significant decrease in TNF- $\alpha$  levels. Also, the meta-analysis by Haghghatdoost *et al.*<sup>44</sup> showed that oral LC supplementation was linked to a small but statistically significant drop in TNF- $\alpha$  levels (WMD =  $-0.37$  pg/dL; 95% CI:  $-0.68, -0.06$  pg/dL;  $P = 0.018$ ). In addition, another meta-analysis found the same result.<sup>45</sup> Reported meta-analysis by Rastgoo *et al.*<sup>19</sup> was published in 2023 and included ten studies up to October 2022. In comparison, our study identified potentially relevant RCTs in December 2023. Furthermore, in their research, a study by Lee *et al.*<sup>20</sup> has been included, in which TNF- $\alpha$  was not among the study's outcomes. According to our subgroup analysis, LC at a dose of only 0.75 and 6 g/day mg/day was effective in TNF- $\alpha$  level reduction. Furthermore, a significant correlation was found in weeks 2, 36, and 48 between the outcomes of subgroup analyses based on the duration of LC consumption expressed in weeks.

All mammals have LC (3-hydroxy-4-N-trimethylammonial-oxidaum butyrate), an amino acid-like substance. This small molecule constitutes the main portion of the "carnitine pool" in the body. The short-, medium-, and long-chain esters referred to as acyl-carnitine are further components of this pool. The most common analog in plasma and other tissues is acetyl L-carnitine.<sup>46</sup> Patients with chronic diseases are often found to have low serum levels of free carnitine.<sup>47</sup> The patients in the present study also often had chronic diseases, which probably had a low serum level of free carnitine. Maybe the administrated doses of LC in the included studies are inadequate to produce enough levels of carnitine to be beneficial.



Intravenous LC was associated with a significant reduction in its levels. Of course, this result was expected because the bioavailability of oral LC is around 5–16%, which is a minimal amount compared to the 100% bioavailability of the injectable form.<sup>48</sup>

The results of the subgroup analysis based on nation indicated that variations in the country could have an impact on the reduction of TNF- $\alpha$  levels. The reason for this difference in the results between countries can be attributed to the difference in the ethnicity of the participants in the study. Compared to non-Hispanic whites, non-obese Mexican Americans have been found to have higher levels of TNF- $\alpha$ .<sup>49</sup> In response to environmental stressors, genetic and epigenomic factors that affect metabolism and inflammation could primarily explain these variations. For instance, variations in a person's reaction to inflammatory stimuli may significantly affect development of both acute and chronic inflammatory disorders.<sup>50</sup> Another reason could be differences in the resting levels of inflammatory markers between races.<sup>51,52</sup>

For future research, it is recommended that the measurement of inflammatory factors be combined with the measurement of serum carnitine levels to determine whether administering LC at different doses in various populations results in a sufficient increase in serum carnitine levels, effectively reducing the level of inflammatory factors. Another suggestion for future studies is to consider the effect of LC intake through diet. Because the main source of LC intake is the diet,<sup>53</sup> the bioavailability of LC in food is much higher than the bioavailability of its supplemental source (54–87%<sup>54</sup> versus 5–16%<sup>48</sup>). Therefore, it seems that the effects of LC, received from the diet, on inflammatory factors and serum carnitine levels cannot be ignored.

The strength of the current study is that it is the only study examining the effect of parenteral LC on TNF- $\alpha$ . This study suggests that there might be a few possible limits. The first is the limited number of studies with various populations, which undoubtedly affected our results. The second was the variety of assessment methods and the dosage, route, and duration of LC administration. This produces even more controversial results. Furthermore, we only included published research in Farsi and English in our search. Finally, it was not possible impossible to perform a meta-analysis with subgroup analysis in different populations due to data heterogeneity. There was some concern about bias in almost half of the included studies, which affected the validity of the findings of our meta-analysis and we did not consider the impact of dietary LC consumption.

## Conclusion

In conclusion, the present meta-analysis showed that LC did not have significant impact on TNF- $\alpha$  levels, generally. However, unlike oral LC, parenteral LC had significantly reduced TNF- $\alpha$  levels. It seems that to reach a comprehensive conclusion and confirmation of the effects of oral LC on TNF- $\alpha$ , well-designed RCTs, with higher

doses and duration of administration, would be helpful.

## Acknowledgments

We would like to appreciate the cooperation of Clinical Research Development Unit, Imam Reza General Hospital, Tabriz, Iran in conducting of this research. This article is based on a PhD thesis and was financially supported by Tabriz University of Medical Sciences under grant number 69197.

## Author Contributions

Farnaz Naeimzadeh: Writing - Original Draft, Methodology, Visualization, Writing - Review & Editing. Amirreza Naseri: Methodology, Formal Analysis, Visualization, Writing - Review & Editing. Sarvin Sanaie: Conceptualization, Methodology, Data Curation, Project administration, Writing - Review & Editing. Seiedhadi Saghaleini: Conceptualization, Methodology, Writing - Review & Editing. Afshin Gharekhani: Conceptualization, Methodology, Supervision, Funding acquisition, Writing - Review & Editing.

## Conflict of Interest

The authors have not disclosed any competing interests.

## Supplementary Data

Supplementary data are available at <https://doi.org/10.34172/PS.2024.13>.

## References

1. Pawelec G, Goldeck D, Derhovanessian E. Inflammation, ageing and chronic disease. *Curr Opin Immunol.* 2014;29:23-8. doi:10.1016/j.coi.2014.03.007
2. Taraz M, Khatami M-R, Gharekhani A, Abdollahi A, Khalili H, Dashti-Khavidaki S. Relationship between a pro- and anti-inflammatory cytokine imbalance and depression in haemodialysis patients. *Eur Cytokine Netw.* 2012;23(4):179-86. doi:10.1684/ecn.2013.0326
3. Gharekhani A, Khatami M-R, Dashti-Khavidaki S, Razeghi E, Abdollahi A, Hashemi-Nazari SS, et al. Effects of oral supplementation with omega-3 fatty acids on nutritional state and inflammatory markers in maintenance hemodialysis patients. *J Renal Nutr.* 2014;24(3):177-85. doi:10.1053/j.jrn.2014.01.014
4. Prasad S, Tyagi AK, Aggarwal BB. Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases. *Exp Biol Med.* 2016;241(8):783-99. doi:10.1177/1535370216638770
5. Panahi Y, Dashti-Khavidaki S, Farnood F, Noshad H, Lotfi M, Gharekhani A. Therapeutic effects of omega-3 fatty acids on chronic kidney disease-associated pruritus: A literature review. *Adv Pharm Bull.* 2016;6(4):509-14. doi:10.15171/apb.2016.064
6. Agrawal M, Shah S, Patel A, Pinotti R, Colombel J-F, Burisch J. Changing epidemiology of immune-mediated inflammatory diseases in immigrants:

- A systematic review of population-based studies. *J Autoimmun.* 2019;105:102303. doi:10.1016/j.jaut.2019.07.002
7. Jang D-i, Lee A-H, Shin H-Y, Song H-R, Park J-H, Kang T-B, et al. The role of tumor necrosis factor alpha (tnf- $\alpha$ ) in autoimmune disease and current tnf- $\alpha$  inhibitors in therapeutics. *Int J Mol Sci.* 2021;22(5):2719. doi:10.3390/ijms22052719
  8. Leone GM, Mangano K, Petralia MC, Nicoletti F, Fagone P. Past, present and (foreseeable) future of biological anti-tnf alpha therapy. *J Clin Med.* 2023;12(4):1630. doi:10.3390/jcm12041630
  9. Askarpour M, Hadi A, Symonds ME, Miraghajani M, Omid S, Sheikhi A, et al. Efficacy of l-carnitine supplementation for management of blood lipids: A systematic review and dose-response meta-analysis of randomized controlled trials. *Nutr, Metab Cardiovasc Dis.* 2019;29(11):1151-67. doi:10.1016/j.numecd.2019.07.012
  10. Pekala J, Patkowska-Sokola B, Bodkowski R, Jamroz D, Nowakowski P, Lochynski S, Librowski T. L-carnitine-metabolic functions and meaning in humans life. *Curr Drug Metab.* 2011;12(7):667-78. doi:10.2174/138920011796504536
  11. de Moraes MS, Guerreiro G, Sitta A, de Moura Coelho D, Manfredini V, Wajner M, et al. Oxidative damage in mitochondrial fatty acids oxidation disorders patients and the in vitro effect of l-carnitine on DNA damage induced by the accumulated metabolites. *Arch Biochem Biophys.* 2020;679:108206. doi:10.1016/j.abb.2019.108206
  12. Emran T, Chowdhury NI, Sarker M, Bepari AK, Hossain M, Rahman GMS, et al. L-carnitine protects cardiac damage by reducing oxidative stress and inflammatory response via inhibition of tumor necrosis factor-alpha and interleukin-1beta against isoproterenol-induced myocardial infarction. *Biomed Pharmacother.* 2021;143:112139. doi:10.1016/j.biopha.2021.112139
  13. Zhang Z, Zhao M, Wang J, Ding Y, Dai X, Li Y. [effect of acetyl-l-carnitine on the insulin resistance of l6 cells induced by tumor necrosis factor-alpha]. *Wei Sheng Yan Jiu.* 2010;39(2):152-4.
  14. Amiri-Moghadam S, Nematy M, Eghtesadi S, Mojarrad M, Jazayeri S, Vosooghnia H, et al. Effects of l-carnitine supplementation on inflammatory factors and malondialdehyde in patients with nonalcoholic steatohepatitis (NASH). *Curr Top Nutraceutical Res* 2015;13(3):135.
  15. Derosa G, Maffioli P, Salvadeo SAT, Ferrari I, Gravina A, Mereu R, et al. Effects of combination of sibutramine and l-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. *Metabolism.* 2011;60(3):421-9. doi:10.1016/j.metabol.2010.03.010
  16. Fu RG. The effect of levocarnitine on nutritional status and lipid metabolism during long-term maintenance hemodialysis. *Acad J Xian Jiaotong Univ.* 2010;4:203-7.
  17. Jirillo E, Altamura M, Munno I, Pellegrino NM, Sabato R, Fabio SD, et al. Effects of acetyl-l-carnitine oral administration on lymphocyte antibacterial activity and tnf- $\alpha$  levels in patients with active pulmonary tuberculosis. A randomized double blind versus placebo study. *Immunopharmacol Immunotoxicol.* 1991;13(1-2):135-46. doi:10.3109/08923979109019696
  18. Shakeri A, Tabibi H, Hedayati M. Effects of l-carnitine supplement on serum inflammatory cytokines, c-reactive protein, lipoprotein (a), and oxidative stress in hemodialysis patients with lp (a) hyperlipoproteinemia. *Hemodial Int.* 2010;14(4):498-504. doi:10.1111/j.1542-4758.2010.00476.x
  19. Rastgoo S, Fateh ST, Nikbaf-Shandiz M, Rasaei N, Aali Y, Zamani M, et al. The effects of l-carnitine supplementation on inflammatory and anti-inflammatory markers in adults: A systematic review and dose-response meta-analysis. *Inflammopharmacology.* 2023;31(5):2173-99. doi:10.1007/s10787-023-01323-9
  20. Lee BJ, Lin JS, Lin YC, Lin PT. Effects of l-carnitine supplementation on oxidative stress and antioxidant enzymes activities in patients with coronary artery disease: A randomized, placebo-controlled trial. *Nutr J.* 2014;13:79. doi:10.1186/1475-2891-13-79
  21. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The prisma extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. *Ann Intern Med.* 2015;162(11):777-84. doi:10.7326/M14-2385
  22. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. Rob 2: A revised tool for assessing risk of bias in randomised trials. *BMJ.* 2019;366:l4898. doi:10.1136/bmj.l4898
  23. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Completing 'summary of findings' tables and grading the certainty of the evidence. *Cochrane handbook for systematic reviews of interventions.* Chichester (UK): John Wiley & Sons; 2019.
  24. Asbaghi O, Sadeghian M, Mozaffari-Khosravi H, Maleki V, Shokri A, Hajizadeh-Sharafabad F, et al. The effect of vitamin d-calcium co-supplementation on inflammatory biomarkers: A systematic review and meta-analysis of randomized controlled trials. *Cytokine.* 2020;129:155050. doi:10.1016/j.cyto.2020.155050
  25. Mahdavi R, Kolahi S, Attari VE, Mahdavi AM. L-carnitine supplementation ameliorates serum tumor necrosis factor-alpha and matrix metalloproteinase-3 in knee osteoarthritis women. *Bangladesh J Pharmacol.* 2017;12(1):28-34. doi:10.3329/bjp.v12i1.30417
  26. Mazdeh M, Abolfathi P, Sabetghadam M, Mohammadi Y, Mehrpooya M. Clinical evidence of acetyl-l-carnitine efficacy in the treatment of acute ischemic stroke: A pilot clinical trial. *Oxid Med Cell Longevity.* 2022;2022:2493053. doi:10.1155/2022/2493053
  27. De Simone C, Tzantzoglou S, Famularo G, Moretti S,

- Paoletti F, Vullo V, Delia S. High dose l-carnitine improves immunologic and metabolic parameters in aids patients. *Immunopharmacology and Immunotoxicology*. 1993;15(1):1-12. doi:10.3109/08923979309066930
28. Delogu G, De Simone C, Famularo G, Fegiz A, Paoletti F, Jirillo E. Anaesthetics modulate tumour necrosis factor  $\alpha$ : Effects of l-carnitine supplementation in surgical patients. Preliminary results. *Mediators Inflamm*. 1993;2:383619. doi:10.1155/S0962935193000730
  29. Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, et al. L-carnitine supplementation to diet: A new tool in treatment of nonalcoholic steatohepatitis—a randomized and controlled clinical trial. *Am J Gastroenterol*. 2010;105(6):1338-45. doi:10.1038/ajg.2009.719
  30. Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, et al. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. *Fundam Clin Pharmacol*. 2011;25(5):642-51. doi:10.1111/j.1472-8206.2010.00888.x
  31. Chi X-G, Ma Z, Zhang W-B, Cai Q, Chen Y-Z, Ding D-L. Effects of high-flux hemodialysis combined with levocarnitine on vascular calcification, microinflammation, hepcidin, and malnutrition of elderly patients on maintenance hemodialysis. *Ann Palliat Med*. 2021;10(3):3286-98.
  32. Lee B-J, Lin J-S, Lin Y-C, Lin P-T. Antiinflammatory effects of l-carnitine supplementation (1000 mg/d) in coronary artery disease patients. *Nutrition*. 2015;31(3):475-9. doi:10.1016/j.nut.2014.10.001
  33. El-sheikh HM, El-Haggar SM, Elbedewy TA. Comparative study to evaluate the effect of l-carnitine plus glimepiride versus glimepiride alone on insulin resistance in type 2 diabetic patients. *Diabetes Metab Syndr*. 2019;13(1):167-73. doi: 10.1016/j.dsx.2018.08.035
  34. Badrasawi M, Shahar S, Zahara AM, Nor Fadilah R, Singh DKA. Efficacy of l-carnitine supplementation on frailty status and its biomarkers, nutritional status, and physical and cognitive function among prefrail older adults: A double-blind, randomized, placebo-controlled clinical trial. *Clin Interventions Aging*. 2016;11:1675-86. doi:10.2147/CIA.S113287
  35. Sawicka AK, Hartmane D, Lipinska P, Wojtowicz E, Lysiak-Szydłowska W, Olek RA. L-carnitine supplementation in older women. A pilot study on aging skeletal muscle mass and function. *Nutrients*. 2018;10(2):255. doi:10.3390/nu10020255
  36. Volek JS, Judelson DA, Silvestre R, Yamamoto LM, Spiering BA, Hatfield DL, et al. Effects of carnitine supplementation on flow-mediated dilation and vascular inflammatory responses to a high-fat meal in healthy young adults. *Am J Cardiol*. 2008;102(10):1413-7. doi:10.1016/j.amjcard.2008.07.022
  37. De Simone C, Tzantzoglou S, Famularo G, Moretti S, Paoletti F, Vullo V, Delia S. High dose l-carnitine improves immunologic and metabolic parameters in aids patients. *Immunopharmacol Immunotoxicol*. 1993;15(1):1-12. doi:10.3109/08923979309066930
  38. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. *J Dermatol Treat*. 2004;15(5):280-94. doi:10.1080/09546630410017275
  39. Liu T, Zhang L, Joo D, Sun S-C. Nf-kb signaling in inflammation. *Signal Transduct Target Ther*. 2017;2(1):17023. doi:10.1038/sigtrans.2017.23
  40. Fatouros IG, Douroudos I, Panagoutsos S, Pasadakis P, Nikolaidis MG, Chatzinikolaou A, et al. Effects of l-carnitine on oxidative stress responses in patients with renal disease. *Med Sci Sports Exerc*. 2010;42(10):1809-18. doi:10.1249/MSS.0b013e3181dbacab
  41. Grivas GV. The role of l-carnitine in distance athletes. *Int J Sports Sci*. 2018;8(5):158-63. doi:10.5923/j.sports.20180805.04
  42. Navarro SL, Kantor ED, Song X, Milne GL, Lampe JW, Kratz M, White E. Factors associated with multiple biomarkers of systemic inflammation. *Cancer Epidemiol Biomarkers Prev*. 2016;25(3):521-31. doi:10.1158/1055-9965.Epi-15-0956
  43. Tzanavari T, Giannogonas P, Karalis KP. Tnf-alpha and obesity. *Curr Dir Autoimmun*. 2010;11:145-56. doi:10.1159/000289203
  44. Haghghatdoost F, Jabbari M, Hariri M. The effect of l-carnitine on inflammatory mediators: A systematic review and meta-analysis of randomized clinical trials. *Eur J Clin Pharmacol*. 2019;75(8):1037-46. doi:10.1007/s00228-019-02666-5
  45. Fathizadeh H, Milajerdi A, Reiner Ž, Amirani E, Asemi Z, Mansournia MA, Hallajzadeh J. The effects of l-carnitine supplementation on indicators of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials. *J Diabetes Metab Disord*. 2020;19(2):1879-94. doi:10.1007/s40200-020-00627-9
  46. Rebouche CJ, Seim H. Carnitine metabolism and its regulation in microorganisms and mammals. *Annu Rev Nutr*. 1998;18(1):39-61. doi:10.1146/annurev.nutr.18.1.39
  47. Böhmer T, Rydning A, Solberg HE. Carnitine levels in human serum in health and disease. *Clinica Chimica Acta*. 1974;57(1):55-61. doi:10.1016/0009-8981(74)90177-6
  48. Harper P, Elwin CE, Cederblad G. Pharmacokinetics of bolus intravenous and oral doses of l-carnitine in healthy subjects. *Eur J Clin Pharmacol*. 1988;35(1):69-75. doi:10.1007/BF00555510
  49. Ho RC, Davy KP, Hickey MS, Melby CL. Circulating tumor necrosis factor alpha is higher in non-obese, non-diabetic mexican americans compared to non-hispanic white adults. *Cytokine*. 2005;30(1):14-21. doi:10.1016/j.cyto.2004.10.015
  50. Stowe RP, Peek MK, Cutchin MP, Goodwin JS. Plasma

- cytokine levels in a population-based study: Relation to age and ethnicity. *J Gerontol.* 2009;65A(4):429-33. doi:10.1093/gerona/glp198
51. Paalani M, Lee JW, Haddad E, Tonstad S. Determinants of inflammatory markers in a bi-ethnic population. *Ethn Dis.* 2011;21(2):142-9.
52. Rhew EY, Manzi SM, Dyer AR, Kao AH, Danchenko N, Barinas-Mitchell E, et al. Differences in subclinical cardiovascular disease between african american and caucasian women with systemic lupus erythematosus. *Transl Res.* 2009;153(2):51-9. doi:10.1016/j.trsl.2008.11.006
53. Evans AM, Fornasini G. Pharmacokinetics of l-carnitine. *Clin Pharmacokinet* 2003;42(11):941-67. doi:10.2165/00003088-200342110-00002
54. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of l-carnitine and acetyl-l-carnitine metabolism. *Ann N Y Acad Sci.* 2004;1033(1):30-41. doi:10.1196/annals.1320.003